RxDoctor Payments Data

Yasser Salem, MD

Cardiovascular Disease · Marinette, WINPI 1033226303

Payments from drug & device makers

$4,666in general payments, 2019–2025

Across 242 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Johnson & Johnson$620
  • AstraZeneca$356
  • Boehringer Ingelheim$352
  • Lexicon Pharmaceuticals, Inc.$266
  • Amgen$248
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,53097%
  • Education$1363%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,666 in reported general payments places this provider in the 70th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$121,701
Medicare patients
373
Services billed
1,202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan318$292,584
EliquisApixaban157$149,494
XareltoRivaroxaban149$126,996
JardianceEmpagliflozin109$112,374
Repatha SureclickEvolocumab95$96,492
FarxigaDapagliflozin Propanediol55$49,845
BrilintaTicagrelor37$35,417
NexletolBempedoic Acid33$19,766
Atorvastatin Calcium749$9,604
VerquvoVericiguat22$7,199
Metoprolol Succinate449$6,730
Varenicline Tartrate14$5,093
Losartan Potassium516$4,617
Torsemide244$4,301
Potassium Chloride151$3,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$1,452$292,584318 claims
PfizerEliquis$35$149,494157 claims
Johnson & JohnsonXarelto$620$126,996149 claims
Boehringer IngelheimJardiance$352$112,374109 claims
AstraZenecaFarxiga, Brilinta$356$85,26392 claims
Esperion Therapeutics, Inc.Nexletol$168$19,76633 claims
MerckVerquvo$236$7,19922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Marinette

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →